Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy Read More »
Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial Read More »
Cell and Gene Therapy Companies Leverage GenScript’s cGMP sgRNA Capability to Accelerate Speed to Market Read More »
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting Read More »
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 Read More »
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma Read More »
